pSivida Limited
Nanotech company reports positive phase 2a trial results in liver cancer
Published in Medicine and Law Weekly, March 18th, 2005
Data from the second patient cohort of the current phase 2a trial has further demonstrated that BrachySil (32-P BioSilicon) is safe and effective in tumor regression with increased efficacy.
Results of the second group of 4 patients, 12 weeks after their BrachySil treatment, revealed an average tumor regression by volume of 80% as determined by CT scanning. In some smaller tumors 100% regression was observed, a level of performance not seen with other intratumoral approaches. The study also...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- Abortion
Bill would require viewing graphic photos before abortion - Akorn, Inc.
Agreement signed to license patent from M.D. Anderson Cancer Center - American Justice Partnership
Legal reform advocacy group commends Georgia's tort reform legislation - American Physical Therapy Association
Members of Congress support affordable rehabilitation services under Medicare - Assisted Suicide
Terminally ill await Supreme Court's ruling on Oregon's assisted suicide law - Bio Holdings International, Ltd.
Japanese patent approved for preparation method of biological glue - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
